Open AccessGenomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)
Author(s) -
Julia González-Rincón,
José Antonio García-Vela,
Sagrario Gómez,
Belén Fernández-Cuevas,
Sara Nova-Gurumeta,
Nuria Pérez-Sanz,
Miguel Alcoceba,
Marcos González,
Eduardo Anguita,
Javier LópezJiménez,
Eva GonzálezBarca,
Lucrecia Yáñez,
Ernesto PérezPersona,
Javier de la Serna,
Miguel Fernández-Zarzoso,
Guillermo Debén,
Francisco Javier Peñalver,
M.C. Fernández,
Jaime Pérez de Oteyza,
María Angeles Andreu,
M. Ángeles Ruíz-Guinaldo,
Raquel Paz-Arias,
MaDolores García-Malo,
Valle Recasens,
Rosa Collado,
Raúl Córdoba,
Belén NavarroMatilla,
Margarita SánchezBeato,
José A. García-Marco
Publication year - 2021
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0257353
Subject(s) - ighv@ , chronic lymphocytic leukemia , chemoimmunotherapy , rituximab , leukemia , biology , gene , mutation , somatic evolution in cancer , oncology , genetics , cancer research , medicine , antibody
Chronic Lymphocytic Leukemia (CLL) is the most prevalent leukemia in Western countries and is notable for its variable clinical course. This variability is partly reflected by the mutational status of IGHV genes. Many CLL samples have been studied in recent years by next-generation sequencing. These studies have identified recurrent somatic mutations in NOTCH1 , SF3B1 , ATM , TP53 , BIRC3 and others genes that play roles in cell cycle, DNA repair, RNA metabolism and splicing. In this study, we have taken a deep-targeted massive sequencing approach to analyze the impact of mutations in the most frequently mutated genes in patients with CLL enrolled in the REM ( rituximab en mantenimiento ) clinical trial. The mutational status of our patients with CLL, except for the TP53 gene, does not seem to affect the good results obtained with maintenance therapy with rituximab after front-line FCR treatment.